Samsung Medical Center, CAR T-Cell Therapy Center

CAR T-cell Therapy Center at Samsung Medical Center is the only institution in Korea that performs CAR T-cell therapy. For the first time in Korea, the procedure has been completed on 11 patients with refractory diffuse large B-cell lymphoma, and about 20 patients are waiting for treatment by the end of this year.

Currently, the CAR T-cell Therapy Center offers Novartis' Kymriah CAR T-cell therapy to patients with diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia patients who are under the age of 25. In addition, clinical trials for CRCO1 developed by a Korean company (Curocell) are underway for patients with refractory diffuse large B-cell lymphoma. Furthermore, being known as the CAR T-cell Therapy hub in Korea, clinical trials for CAR T-cell therapy developed by Janssen are also in progress for patients with relapsed/refractory multiple myeloma.

CAR T-cell treatment requires collaboration with various departments within the hospital prior to the start of treatment. Specifically, numerous experts in related fields such as infectious disease, neurology, cardiology, and intensive care participates in the comprehensive management post treatment.

The CAR T-cell therapy center is currently participating in the “Research-oriented Hospital R&D Project” by the Ministry of Health and Welfare, and is expected to become a cell therapy center that leads high-level cell therapy and patient-specific treatment for hematological oncology patients.